Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, non-prostate

2682 - Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): a global germ cell cancer group (G3) study


09 Oct 2016


Genitourinary tumours, non-prostate


Ben Tran


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


B. Tran1, J.M. Ruiz-Morales2, E. González Billalabeitia3, E. Amir4, C. Seidel5, C. Bokemeyer5, C. Fankhauser6, T. Hermanns6, A. Rumyantsev7, A. Tryakin7, M. Brito8, A. Flechon9, D. Castellano10, X. Garcia del Muro11, A. Hamid12, G. Palmieri13, R. Kitson14, A. Reid14, D. Heng15, P. Bedard4

Author affiliations

  • 1 Medical Oncology, The Royal Melbourne Hospital, 3050 - Parkville/AU
  • 2 Medical Oncology, Tom Baker Cancer Centre, Calgary/CA
  • 3 Servicio De Hematología Y Oncología Médica, Hospital Universitario Morales Meseguer, Murcia/ES
  • 4 Medical Oncology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 5 Dept. Hemato/oncology, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, 20246 - Hamburg/DE
  • 6 Department Of Urology, University Hospital Zürich, Zürich/CH
  • 7 Medical Oncology, N. N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 8 Medical Oncology, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisboa/PT
  • 9 Medical Oncology, Centre Léon Bérard, Lyon/FR
  • 10 Medical Oncology, University Hospital 12 De Octubre, Madrid/ES
  • 11 Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona/ES
  • 12 Medical Oncology, Austin Hospital, Heidelberg/AU
  • 13 Medical Oncology, Università Degli Studi di Napoli Federico II, Napoli/IT
  • 14 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 15 Medical Oncology, Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA


Abstract 2682


Prior data indicate that large RPLN significantly increases the risk of VTE in pts with mGCT receiving first line platinum based chemotherapy (chemo). The aim of this multinational G3 study was to validate large RPLN as a risk factor for VTE and evaluate other predictive factors.


Data were collected retrospectively from sequential pts with mGCT receiving first line chemo from 2000-2014 at 22 centres. Pre-defined variables of interest included IGCCCG risk classification, axial long axis diameter of largest RPLN, Khorana score (validated predictor for chemo associated VTE), LDH, prior VTE and presence of venous access device (VAD). VTE occurring at baseline, during chemo and within 90 days of completion were analysed. Pts receiving thromboprophylaxis (TP) were excluded. Predictive accuracy was assessed using logistic regression and discriminatory accuracy explored using area under the receiver operating curve (AUC).


Data from 1135 pts were collected. Median age was 31 (range 10-74). Testicular primary (92%), non-seminoma histology (72%) and BEP chemo (82%) were most common. IGCCCG risk distribution was 64% good, 20% intermediate and 16% poor. VTE occurred in 150 pts (13%). RPLN >3.5cm demonstrated highest discriminatory accuracy (AUC 0.68, p 3.5cm was associated with significantly higher risk of VTE (22% versus 8%, OR 3.4, p 


This study confirms large RPLN (>3.5cm) as an independent risk factor for VTE in mGCT pts receiving first line chemo. Prospective trials examining TP in this high risk population are warranted.

Clinical trial identification

Not applicable

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings